Actively Recruiting
Phase II Study of SYS6041 Combination Therapy Evaluating Safety and Efficacy in Recurrent Ovarian Cancer
Led by CSPC Megalith Biopharmaceutical Co.,Ltd. · Updated on 2026-08-31
171
Participants Needed
1
Research Sites
69 weeks
Total Duration
AI-Summary
What This Trial Is About
This clinical trial is an open-label, multicenter Phase II study investigating SYS6041 combination therapy in subjects with recurrent ovarian cancer. The study aims to assess the safety, tolerability, pharmacokinetics, and preliminary effectiveness of SYS6041 when combined with other agents. Participants include those with high-grade serous ovarian, epithelial fallopian tube carcinoma, or primary peritoneal cancer who have experienced disease progression or intolerance to recent treatments. Participants will receive SYS6041 combined with various agents such as carboplatin, paclitaxel, bevacizumab, or enlonstobart. Each treatment cycle lasts three weeks, and participants continue until disease progression, intolerable side effects, starting new anti-tumor therapy, withdrawal, loss to follow-up, or death. Different treatment groups receive distinct combinations, with dosing schedules every three weeks through intravenous administration. During the study, participants will undergo assessments including monitoring of dose-limiting toxicities, adverse events, pharmacokinetic measures, and tumor response evaluations. Follow-up for outcomes like progression-free survival and overall survival may last up to approximately three years. Safety and response data will be collected throughout treatment and up to 30 days after the last dose, with some measures tracked for several years to evaluate long-term effects.
CONDITIONS
Brief Title
A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer
Research Team
C
Clinical Trials Information Group officer
X
Xiaohua Wu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here